PCP
DNLI icon

Proficio Capital Partners’s Denali Therapeutics DNLI Stock Holding History

Proficio Capital Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-46
Closed -$1K – 510
2019
Q2 		$1K Buy
+46
New +$1.03K ﹤0.01% 1713

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Proficio Capital Partners's DNLI Position: Q3 2019 in Review

Proficio Capital Partners sold out of Denali Therapeutics (DNLI) in Q3 2019, closing a stake of 46 shares — an estimated $1K sold.

Proficio Capital Partners first reported a position in DNLI in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 118 funds tracked by Wall St. Rank hold DNLI as of Q3 2019.

  • Proficio Capital Partners reported no remaining Denali Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 46 Denali Therapeutics shares in Q3 2019, an estimated $1K.
  • Proficio Capital Partners first reported a position in Denali Therapeutics in Q2 2019 and held it in 1 quarter.
  • Proficio Capital Partners's Denali Therapeutics position peaked at $1K in Q2 2019.
  • 118 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.